<code id='BC90922CA5'></code><style id='BC90922CA5'></style>
    • <acronym id='BC90922CA5'></acronym>
      <center id='BC90922CA5'><center id='BC90922CA5'><tfoot id='BC90922CA5'></tfoot></center><abbr id='BC90922CA5'><dir id='BC90922CA5'><tfoot id='BC90922CA5'></tfoot><noframes id='BC90922CA5'>

    • <optgroup id='BC90922CA5'><strike id='BC90922CA5'><sup id='BC90922CA5'></sup></strike><code id='BC90922CA5'></code></optgroup>
        1. <b id='BC90922CA5'><label id='BC90922CA5'><select id='BC90922CA5'><dt id='BC90922CA5'><span id='BC90922CA5'></span></dt></select></label></b><u id='BC90922CA5'></u>
          <i id='BC90922CA5'><strike id='BC90922CA5'><tt id='BC90922CA5'><pre id='BC90922CA5'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:1

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          CRISPR technology availability, affordability needs to be expanded
          CRISPR technology availability, affordability needs to be expanded

          Fromleft,STAT'sJasonMast;JuliaVitarello,founder&CEOofMila’sMiracleFoundation;andFyodorUrnov,agen

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          U.K. officials, researchers try to ease path for bespoke genetic treatments

          AdobeLONDON—Widespreadgenetictestingaswellasthedevelopmentofcutting-edge,customizedgenetictherapiesh